{"id":7896,"date":"2016-11-04T00:00:00","date_gmt":"2016-11-03T23:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2016\/11\/04\/descoberta-una-causa-de-resistencia-multiple-a-la-quimioterapia-del-cancer\/"},"modified":"2020-05-13T19:47:03","modified_gmt":"2020-05-13T17:47:03","slug":"descoberta-una-causa-de-resistencia-multiple-a-la-quimioterapia-del-cancer","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2016\/11\/descoberta-una-causa-de-resistencia-multiple-a-la-quimioterapia-del-cancer\/","title":{"rendered":"Descoberta una causa de resist\u00e8ncia m\u00faltiple a la quimioter\u00e0pia del c\u00e0ncer"},"content":{"rendered":"

Un nou estudi desenvolupat per investigadors de l’Institut de Recerca Biom\u00e8dica de Bellvitge (IDIBELL) descobreix una causa de la resist\u00e8ncia m\u00fatiple en la quimioter\u00e0pia del c\u00e0ncer. El treball, publicat avui a la revista Proceedings of the National Academy of Science <\/em>(PNAS), l’\u00f2rgan d’expressi\u00f3 de l’Acad\u00e8mia de Ci\u00e8ncies dels Estats Units, ha estat realitzat pel grup del Dr. Manel Esteller, director del Programa d’Epigen\u00e8tica i Biologia del C\u00e0ncer (PEBC) de l’IDIBELL, investigador ICREA i Professor de Gen\u00e8tica de la Universitat de Barcelona. <\/p>\n

La introducci\u00f3 de la quimioter\u00e0pia del c\u00e0ncer va suposar una revoluci\u00f3 per al tractament d’aquesta malaltia en aquells casos en qu\u00e8 la curaci\u00f3 no \u00e9s ja possible nom\u00e9s amb la simple extirpaci\u00f3 del tumor. La quimioter\u00e0pia s’ha demostrat efectiva en un ampli ventall de pacients, per\u00f2 un dels seus principals problemes \u00e9s l’aparici\u00f3 de resist\u00e8ncia contra el medicament anti-tumoral usat. No obstant aix\u00f2, des de fa d\u00e8cades se sap que hi ha tumors que presenten una resist\u00e8ncia creuada contra diferents f\u00e0rmacs des del seu inici, quan encara no han estat tractats. <\/p>\n

“Hem trobat que un 10% de tumors de c\u00f2lon i est\u00f3mac presenten la p\u00e8rdua d’una mol\u00e8cula anomenada TP53TG1, qu\u00e8 en c\u00e8l\u00b7lules sanes \u00e9s l\u2019encarregada de prevenir l’activaci\u00f3 de la prote\u00efna YBX1. Sense la vigil\u00e0ncia de TP53TG1 en aquests tumors gastrointestinals, YBX1 s’encarrega d\u2019anar al nucli de la c\u00e8l\u00b7lula i activar centenars de oncogens que impediran la mort de les c\u00e8l\u00b7lules malignes produ\u00efda pels f\u00e0rmacs antitumorals”, comenta el Dr. Manel Esteller. <\/p>\n

L’espectre de resist\u00e8ncies indu\u00efdes per aquest mecanisme \u00e9s extens i inclou f\u00e0rmacs emprats en el tractament com\u00fa d’aquest tipus de c\u00e0ncers, com el 5-fluorouracil, l\u2019oxiplat\u00ed o l\u2019irinotec\u00e0, per\u00f2 tamb\u00e9 medicaments dirigits a dianes moleculars recents, com ara els inhibidors de cinases. <\/p>\n

A partir dels resultats publicats a PNAS, explica el Dr. Esteller, “ens falta per estudiar si queda algun f\u00e0rmac que s’escapi a aquest mecanisme de quimioresist\u00e8ncia m\u00faltiple i tamb\u00e9 explorar si tornar l’activitat a la mol\u00e8cula TP53TG1 significaria recuperar la sensibilitat d’aquests tumors als f\u00e0rmacs analitzats, cosa que representaria un benefici cl\u00ednic per a aquests pacients.”<\/p>\n","protected":false},"excerpt":{"rendered":"

Un nou estudi desenvolupat per investigadors de l’Institut de Recerca Biom\u00e8dica de Bellvitge (IDIBELL) descobreix una causa de la resist\u00e8ncia m\u00fatiple en la quimioter\u00e0pia del c\u00e0ncer. El treball, publicat avui a la revista Proceedings of the National Academy of Science (PNAS), l’\u00f2rgan d’expressi\u00f3 de l’Acad\u00e8mia de Ci\u00e8ncies dels Estats Units, ha estat realitzat pel grup […]<\/p>\n","protected":false},"author":6,"featured_media":10723,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7896","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar"],"publishpress_future_action":{"enabled":false,"date":"2024-11-29 20:57:19","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7896"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7896\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10723"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}